We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+34.9%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$123M
AUM Growth
+$21.1M
Cap. Flow
+$8.21M
Cap. Flow %
6.67%
Top 10 Hldgs %
62.1%
Holding
78
New
19
Increased
23
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$9.75M
2
EOLS icon
Evolus
EOLS
+$4.83M
3
OABI icon
OmniAb
OABI
+$3.92M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$2.72M
5
ABEO icon
Abeona Therapeutics
ABEO
+$2.57M

Top Sells

Rank Stock Value
1
INDV icon
Indivior Pharmaceuticals
INDV
+$5.23M
2
ITOS
iTeos Therapeutics
ITOS
+$3.09M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$2.52M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$2.39M
5
ANIK icon
Anika Therapeutics
ANIK
+$2.02M

Sector Composition

Rank Sector Weight
1 Healthcare 99.76%
2 Financials 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
1
Verastem
VSTM
$530M
$23.6M 19.17%
2,670,032
+1,309,646
+96% +$9.75M
ADMA icon
2
ADMA Biologics
ADMA
$2.02B
$10.8M 8.81%
739,000
-11,000
-1% -$189K
EOLS icon
3
Evolus
EOLS
$377M
$9.43M 7.67%
1,536,391
+619,891
+68% +$4.83M
ZVRA icon
4
Zevra Therapeutics
ZVRA
$755M
$7.7M 6.26%
810,000
+34,380
+4% +$345K
NKTR icon
5
Nektar Therapeutics
NKTR
$2.31B
$4.84M 3.93%
85,000
+34,800
+69% +$1.15M
DAWN
6
DELISTED
Day One Biopharmaceuticals
DAWN
$4.56M 3.71%
647,382
+197,382
+44% +$1.36M
XOMA
7
DELISTED
Xoma
XOMA
$4.45M 3.62%
115,459
-36,684
-24% -$1.14M
ACAD icon
8
Acadia Pharmaceuticals
ACAD
$4.38B
$3.72M 3.03%
174,544
-50,456
-22% -$1.19M
ENTA icon
9
Enanta Pharmaceuticals
ENTA
$400M
$3.65M 2.97%
305,000
-299,066
-50% -$2.39M
XFOR icon
10
X4 Pharmaceuticals
XFOR
$360M
$3.61M 2.94%
+1,056,338
New +$2.72M
OABI icon
11
OmniAb
OABI
$307M
$3.43M 2.79%
+2,142,857
New +$3.92M
SRZN icon
12
Surrozen
SRZN
$255M
$3.22M 2.62%
250,146
-55,883
-18% -$586K
TELA icon
13
TELA Bio
TELA
$32.7M
$3.21M 2.61%
2,155,519
+71,757
+3% +$126K
INDV icon
14
Indivior Pharmaceuticals
INDV
$4.79B
$2.41M 1.96%
100,000
-250,000
-71% -$5.23M
ABEO icon
15
Abeona Therapeutics
ABEO
$399M
$2.38M 1.94%
450,970
+405,970
+902% +$2.57M
GERN icon
16
Geron
GERN
$924M
$2.19M 1.78%
1,600,000
+600,000
+60% +$799K
PMVP icon
17
PMV Pharmaceuticals
PMVP
$71.5M
$1.92M 1.56%
1,370,139
+524,171
+62% +$725K
EDSA icon
18
Edesa Biotech
EDSA
$63.6M
$1.7M 1.38%
+687,500
New +$1.59M
AYTU icon
19
AYTU BioPharma
AYTU
$23.1M
$1.68M 1.36%
891,855
+79,179
+10% +$183K
SLNO
20
DELISTED
Soleno Therapeutics
SLNO
$1.62M 1.32%
+24,000
New +$1.78M
KZR
21
DELISTED
Kezar Life Sciences
KZR
$1.49M 1.21%
383,182
+213,323
+126% +$875K
ALMS
22
Alumis Inc
ALMS
$3.65B
$1.2M 0.97%
300,000
-49,615
-14% -$204K
IKT icon
23
Inhibikase Therapeutics
IKT
$331M
$1.19M 0.97%
735,019
+1,226
+0.2% +$2.12K
BIOA
24
BioAge Labs
BIOA
$1.01B
$1.11M 0.9%
188,571
+37,486
+25% +$176K
ARDX icon
25
Ardelyx
ARDX
$1.28B
$1.1M 0.9%
200,000
-355,000
-64% -$1.93M
1
2 3 4

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Stonepine Capital Management held 78 positions worth $123M, up 21% from $102M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Stonepine Capital Management deployed $8.21M of net new capital in Q3 2025, opening 19 new positions and adding to 23 existing holdings. Its largest new stake was OmniAb: 2,142,857 shares worth $3.43M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Indivior Pharmaceuticals, an estimated $5.23M trimmed.

  • Stonepine Capital Management's largest Q3 2025 buy was OmniAb: 2,142,857 shares worth $3.43M.
  • Stonepine Capital Management added most to Verastem in Q3 2025, an estimated $9.75M increase.
  • Stonepine Capital Management's biggest Q3 2025 reduction was Indivior Pharmaceuticals, cutting an estimated $5.23M.
  • Stonepine Capital Management fully exited iTeos Therapeutics in Q3 2025, selling an estimated $3.09M.
  • Stonepine Capital Management's ten largest holdings make up 62% of its $123M portfolio in Q3 2025.
  • Stonepine Capital Management opened 19 new positions and closed 20 in Q3 2025.
  • Stonepine Capital Management's portfolio value rose 21% quarter-over-quarter to $123M.

Based on Stonepine Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.